For any queries related to information found on this poster please contact Eric Van Cutsem (eric.vancutsem@uzleuven.be).

CRUK; MRC; BRC-Imperial; NIHR; CUP Foundation. GA has received research funding from Servier. CB has attended advisory boards for Roche, Merck, Servier, Amgen, Sanofi, and Eisai. G-JC has received research funding from Servier. MF has received research funding from Servier. KLK has received research funding from Servier. VM has received research funding from Servier. MPS has attended advisory boards for Roche, Merck, Servier, Amgen, Sanofi, and Eisai. HW has received honoraria, attended advisory boards, received a research grant from Roche, Merck, Servier, Amgen, Sanofi, and Eisai. The phase II C-TASK FORCE study was evaluated by Simone Tait of Springer Healthcare Communications, and supported by Institut de Recherches Internationales Servier, Suresnes, France; Zentiva Healthcare; Laboratoires Lavelle and Lavois, Belgium. Funded by Servier.

References

Efficacy
- Median PFS was 9.2 months with TT-B and 7.8 months with C-B giving a hazard ratio (HR) of 0.71 (95% confidence interval [CI] 0.48, 1.06) to TT-B versus C-B (Figure 3).

Summary
- OS, ORR, DCR, Median OS 18.00 (95% CI 15.18, NA)
- Median OS 16.20 (95% CI 13.72, 18.68)
- Median OS 18.00 (95% CI 15.18, NA)
- Median OS 15.00 (95% CI 12.50, 17.50)

Table 3. Response to treatment.

Table 4. Non-haematological AEs occurring in >10% of patients.

Table 5. Hematological toxicities (as treated population).

Table 2. PFS subgroup analyses.

Table 1. Patient baseline demographics and characteristics.

Results

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis


Efficacy
- Median PFS was 9.2 months with TT-B and 7.8 months with C-B giving a hazard ratio (HR) of 0.71 (95% confidence interval [CI] 0.48, 1.06) to TT-B versus C-B (Figure 3).

Summary
- OS, ORR, DCR, Median OS 18.00 (95% CI 15.18, NA)
- Median OS 16.20 (95% CI 13.72, 18.68)
- Median OS 18.00 (95% CI 15.18, NA)
- Median OS 15.00 (95% CI 12.50, 17.50)

Table 3. Response to treatment.

Table 4. Non-haematological AEs occurring in >10% of patients.

Table 5. Hematological toxicities (as treated population).

Table 2. PFS subgroup analyses.

Table 1. Patient baseline demographics and characteristics.

Results

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis


Efficacy
- Median PFS was 9.2 months with TT-B and 7.8 months with C-B giving a hazard ratio (HR) of 0.71 (95% confidence interval [CI] 0.48, 1.06) to TT-B versus C-B (Figure 3).

Summary
- OS, ORR, DCR, Median OS 18.00 (95% CI 15.18, NA)
- Median OS 16.20 (95% CI 13.72, 18.68)
- Median OS 18.00 (95% CI 15.18, NA)
- Median OS 15.00 (95% CI 12.50, 17.50)

Table 3. Response to treatment.

Table 4. Non-haematological AEs occurring in >10% of patients.

Table 5. Hematological toxicities (as treated population).

Table 2. PFS subgroup analyses.

Table 1. Patient baseline demographics and characteristics.